How Do Viruses Avoid Inhibition by Endogenous Cellular MicroRNAs?

Bryan R. Cullen*

Department of Molecular Genetics & Microbiology and Center for Virology, Duke University Medical Center, Durham, North Carolina, United States of America

Introduction

MicroRNAs (miRNAs) are an extensive family of small regulatory RNAs that function by binding to complementary miRNAs, primarily in the 3' untranslated region (3'UTRs), and then inhibiting their expression by reducing mRNA translation and/or stability [1]. MiRNAs are initially transcribed as long primary miRNAs, which are sequentially processed by the RNase III enzymes Drosha, in the nucleus, and Dicer, in the cytoplasm, to generate the mature, ~22-nt miRNA [2]. This is then loaded into the RNA Induced Silencing Complex (RISC), which consists minimally of one of the four mammalian Argonaute proteins, Ago1 to Ago4, as well as a member of the GW182 protein family. MiRNAs function as guide RNAs to target RISC to complementary target sites for endogenous miRNAs [19]. In some instances, this induction facilitates viral replication and/or regulates viral entry or exit from latency [9]. While certain viruses can clearly benefit from cellular miRNAs, it has been unclear how viruses avoid inhibition of viral mRNA function by cellular miRNAs. Indeed, several reports demonstrating inhibition of viruses by cellular miRNAs have been published [13–15]. However, especially given that cellular miRNAs are highly conserved during evolution [1], it seems unlikely that viruses would fail to evolve mechanisms to prevent cellular miRNA-mediated inhibition in their normal target tissues. What these might be, however, is currently unclear. Several possible mechanisms can be proposed:

1) Viruses block miRNA function. This appears rare, as virus-infected cells generally contain normal levels of miRNAs, and most viruses can be inhibited by specific small interfering RNAs (siRNAs), which function indistinguishably from miRNAs in mammalian cells [16], or by insertion of target sites for endogenous cellular miRNAs into viral transcripts [17–20]. Indeed, the use of inserted cellular miRNA target sites as a way of inhibiting viral replication in tissues that express the cognate endogenous miRNA, while allowing unhindered viral replication in cells that lack this miRNA, has considerable potential in facilitating the development of novel attenuated viral vaccines or in targeting oncolytic viral vectors away from normal tissues [17–20].

2) Viruses evolve to avoid 3'UTR targets complementary to cellular miRNAs. Because full complementarity to the seed is generally critical for miRNA inhibition, single nucleotide mutations should block inhibition [1]. However, for viruses that can replicate in several different tissues, each expressing more than 50 distinct miRNAs, complete avoidance of all miRNAs may be very difficult to achieve. Nevertheless, while some DNA viruses also express miRNAs, including adenovirus and polyoma viruses, miRNAs have not been detected in any RNA viruses examined so far, with the exception of the retrovirus bovine leukemia virus (BLV), which transcribes short, pol III-driven miRNA precursors from integrated BLV proviruses [10]. Viruses can also benefit from cellular miRNA species, with the clearest example being Hepatitis C virus (HCV), which requires miR-122 for replication [3]. Moreover, several other viruses have been reported to induce specific cellular miRNAs, and it has been demonstrated that, in some instances, this induction facilitates viral replication in culture, apparently by down-regulating specific cellular mRNA targets with antiviral potential [11,12].

Virus and MicroRNAs

Upon infection of a cell, viruses encounter a wide range of miRNA species, generally more than 50 different miRNAs per cell, and these miRNAs vary greatly between tissues. For example, miR-122 is expressed at very high levels in hepatocytes, but is absent from almost all other cells, while miR-1 is primarily expressed in muscle tissue and miR-128 in neuronal cells [5–7]. Indeed, many of the more than 1000 known human miRNA species show a tissue-specific expression pattern [8], meaning that viruses that infect multiple cell types need a way to avoid inhibition by a wide range of miRNAs with distinct mRNA-targeting specificities.

Analyses of the interactions of viruses with cellular miRNAs have revealed that viruses can influence cellular miRNA biogenesis and effector mechanisms in several different ways. Viruses can clearly benefit from miRNA expression. For example, almost all herpesviruses that have been examined express substantial numbers of miRNAs, and these can facilitate viral replication and/or regulate viral entry or exit from latency [9]. While some DNA viruses also express miRNAs, including adenovirus and polyoma viruses, miRNAs have not been detected in any RNA viruses examined so far, with the exception of the retrovirus bovine leukemia virus (BLV), which transcribes short, pol III-driven miRNA precursors from integrated BLV proviruses [10]. Viruses can also benefit from cellular miRNA species, with the clearest example being Hepatitis C virus (HCV), which requires miR-122 for replication [3]. Moreover, several other viruses have been reported to induce specific cellular miRNAs, and it has been demonstrated that, in some instances, this induction facilitates viral replication in culture, apparently by down-regulating specific cellular mRNA targets with antiviral potential [11,12].

Citation: Cullen BR (2013) How Do Viruses Avoid Inhibition by Endogenous Cellular MicroRNAs? PLoS Pathog 9(11): e1003694. doi:10.1371/journal.ppat.1003694

Editor: Richard C. Condit, University of Florida, United States of America

Published November 7, 2013

Copyright: © 2013 Cullen. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by National Institutes of Health research grants R01-DA030086 and R01-AI067968. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The author has declared that no competing interests exist.

* E-mail: bryan.cullen@duke.edu
especially for viruses that display a narrow tissue tropism, this mechanism seems very likely to be important.

3) **Viruses evolve very short 3’UTRs.** RISC recruitment to open reading frames (ORFs) does not effectively inhibit mRNA function, most probably because translating ribosomes sweep bound RISCs off the mRNA [1]. Therefore, mRNAs with very short 3’UTRs would be expected to be relatively refractory to miRNA-mediated inhibition. In fact, many RNA viruses express mRNAs bearing short 3’UTRs, and the short 3’UTRs that are present are often highly structured, which is predicted to also inhibit RISC binding [4]. RNA virus families that appear likely to use this strategy to avoid inhibition by endogenous cellular miRNAs include flaviviruses, picornaviruses, rhadoviruses, and reoviruses.

4) **Viruses evolve structured 3’UTRs.** Some viruses, especially retroviruses, alphaviruses, and coronaviruses, contain extensive 3’UTRs in at least some viral mRNA species. For example, the HIV-1 mRNA that encodes Gag and Gag-Pol has a 3’UTR that is several thousand nucleotides in length. Similarly, the coronavirus mRNA encoding the viral ORF1a and ORF1b proteins has a 3’UTR more than 10,000 nucleotides in length. How do these very long 3’UTRs avoid functioning as targets for multiple miRNAs? One possibility is that these 3’UTRs have evolved high levels of RNA secondary structure, which would be predicted to globally restrict binding by miRNA-programmed RISCs [4].

Relatively little is known about the secondary structure of viral RNAs, although some data suggest that high levels of secondary structure are a common feature [23]. One viral RNA that has been examined in detail is the HIV-1 RNA genome, which also functions as the mRNA for the viral Gag and Gag-Pol proteins. This RNA has been shown to fold into an extensive secondary structure with relatively few areas that are unfolded and hence, presumably, are available for RISC binding [24]. This prediction has been validated by a comprehensive analysis of the susceptibility of the HIV-1 genome to small interfering RNAs (siRNAs), which in mammalian cells function indistinguishably from miRNAs [16]. These researchers generated over 9,000 siRNAs specific for the HIV-1 genome by sliding the siRNA target along the viral genome by one-nucleotide increments [25]. Relatively few of these siRNAs were found to inhibit HIV-1 replication and gene expression effectively, and those that did were predicted to bind to the few regions of the viral RNA genome that, using biochemical approaches, were predicted to adopt an open, unfolded conformation [24,25].

Recently, the ability of the HIV-1 genome to bind to endogenous cellular miRNAs in relevant target cells (CD4+ T cells) or in a non-physiological target cell (HeLa cells) has been examined using a technology called photo-activatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP). The PAR-CLIP technique involves pulsing cells with the highly photoactivatable uridine analogue 4-thiouridine and then crosslinking endogenous RNAs to bound proteins by irradiation at 365 nm [26]. Crosslinked proteins, and the bound RNAs, are recovered by immunoprecipitation of RISC using an Ago2-specific monoclonal antibody and the binding site footprinted by RNase treatment. The RISC binding sites are then comprehensively identified by deep sequencing of these small RNAs to generate sequence clusters that can be aligned to endogenous miRNA species.

Analysis of RISC binding to the HIV-1 genome indeed identified several binding sites that were occupied by RISCs programmed by endogenous cellular miRNAs and some of these could be shown, by indicator assays, to confer a modest repression of mRNA function [27]. However, perhaps the more interesting finding was that viral RNAs, despite contributing more than 10% of the total mRNA transcriptome in HIV-1 infected cells, in fact gave rise to only approximately 0.2% of all assignable RISC binding sites, with the remaining approximately 99.8% being contributed by cellular miRNAs. That is, viral mRNAs are, at a minimum, 50-fold less likely to bind RISC than are cellular mRNAs, consistent with the idea that HIV-1-encoded miRNAs, at least, have evolved to globally avoid cellular miRNAs by adopting RNA secondary structures that preclude RISC binding.

While a more complete understanding of the interaction of viruses with cellular miRNAs must await a more detailed dissection of the effect of endogenous miRNAs on a wide range of viral species, current data suggest that viruses have likely evolved a number of strategies to avoid inhibition by these ubiquitous cellular regulatory RNAs. Whether the perturbation of these avoidance strategies has the potential to lead to the development of reagents that are useful in disease prevention, such as novel forms of attenuated viral vaccines, remains to be determined.

References

1. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233.
2. Cullen BR (2004) Transcription and processing of human microRNA precursors. Mol Cell 16: 861–863.
3. Loeb GB, Khan AA, Caner D, Haati JB, Shendure J, et al. (2012) Transcriptome-wide miR-155 binding map reveals widespread noncanonical microRNA targeting. Mol Cell 48: 760–770.
4. Amers S, Martinez J, Schroeder R (2007) Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130: 101–112.
5. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309: 1577–1580.
6. Kwon C, Hsu Z, Olson EN, Srivastava D (2005) MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci U S A 102: 18906–18911.
7. Shakhy RL, Cullen BR (2011) Reduced expression of brain-enriched microRNAs in glialblastos in permits targeted regulation of a cell death gene. PLoS ONE 6: e24248. doi: 10.1371/journal.pone.0024248.
8. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, et al. (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401–1414.
9. Grunthoff A, Sullivan CS (2011) Virus-encoded microRNAs. Virology 411: 325–343.
10. Kincaid RP, Burke JM, Sullivan CS (2012) RNA virus microRNA that mimics a B-cell oncomiR. Proc Natl Acad Sci U S A 109: 3077–3082.
11. Linnstaedt SD, Gottwein E, Shkaly RL, Luftig MA, Cullen BR (2010) Virally induced cellular microRNA miR-153 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol 84: 11659–11678.
12. Ho BC, Yu SL, Chen JJ, Chang SY, Yan BS, et al. (2011) Enterovirus-induced miR-141 contributes to shut off of host protein translation by targeting the translation initiation factor eIF4E. Cell Host Microbe 9: 50–69.
13. Lecellier CH, Dunoyer P, Arak R, Lehmann-Chen J, Esquen S, et al. (2005) A cellular microRNA mediates antiviral defense in human cells. Science 308: 557–560.
14. Zheng Z, Xe K, Wang M, He S, Li Q, et al. (2013) Human microRNA hsa-mir-296-5p suppresses enterovirus 71 replication by targeting the viral genome. J Virol 87: 5643–5656.
15. Otsuka M, Jingu Q, Georgel P, New I, Chen J, et al. (2007) Hypersusceptibility to vesicular stomatitis virus infection in Dicer-1-deficient mice is due to impaired miR24 and miR93 expression. Immunity 27: 123–134.
16. Zeng Y, Yi R, Cullen BR (2003) MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A 100: 9779–9784.
17. Yooxes N, Hakkarainen T, Hemminki A, Visakorpi T, Andino R, et al. (2008) Generation of a conditionally replicating adenovirus based on targeted destruction of E1A microRNA by a cell type-specific MicroRNA. J Virol 82: 11099–11105.
10. Kelly EJ, Hadac EM, Greiner S, Russell SJ (2008) Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 14: 1278–1283.
11. Langlois RA, Albrecht RA, Kimble B, Sutton T, Shapiro JS, et al. (2013) MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nat Biotechnol.
12. Barnes D, Kunitomi M, Vignuzzi M, Saksela K, Andino R (2008) Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4: 239–248.
13. Backes S, Shapiro JS, Sabin LR, Pham AM, Reyes I, et al. (2012) Degradation of host microRNAs by poxvirus poly(A) polymerase reveals terminal RNA methylation as a protective antiviral mechanism. Cell Host Microbe 12: 200–210.
14. Sanghvi VR, Steel LF (2011) A re-examination of global suppression of RNA interference by HIV-1. PLoS ONE 6: e17246. doi: 10.1371/journal.pone.0017246.
15. Davis M, Sagan SM, Pezacki JP, Evans DJ, Simmonds P (2008) Bioinformatic and physical characterizations of genome-scale ordered RNA structure in mammalian RNA viruses. J Virol 82: 11824–11836.
16. Watts JM, Dang KK, Gordeuk RV, Leonard CW, Beas JW, Jr., et al. (2009) Architecture and secondary structure of an entire HIV-1 RNA genome. Nature 460: 711–716.
17. Tan X, Lu ZJ, Gao G, Xu Q, Hu L, et al. (2012) Tiling genomes of pathogenic viruses identifies potent antiviral shRNAs and reveals a role for secondary structure in shRNA efficacy. Proc Natl Acad Sci U S A 109: 869–874.
18. Hafner M, Landthaler M, Burger L, Khorshid M, Hauser J, et al. (2010) Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141: 129–141.
19. Whinam AW, Bogerd HP, Flores O, Ho P, Powers JG, et al. (2013) In-depth analysis of the interaction of HIV-1 with cellular microRNA biogenesis and effector mechanisms. mBio 4: e00193.